Novo Nordisk B A/S (NOVO-B.CO)

Novo Nordisk B A/S has an AlphaScore of 64/100 in the healthcare sector as of October 11, 2026. The company posts a high net margin of 33.14% and an elevated return on equity of 59.81%, demonstrating elite profitability and exceptional operational efficiency. A primary strength is its high quality subScore of 80. A key risk is its subdued growth subScore of 30, reflecting limited expansion momentum in the current snapshot.

Written 11/10/2026, 00:41:12 UTC · Snapshot 11/10/2026